STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney general
Gilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced…
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 721 articles · page 1 of 21 · fetched 6 minutes ago
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma…
Read at source →
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Nutrition experts press White House to release ultra-processed food definition
MAHA allies and nutrition experts want the Trump administration to act on ultra-processed foods before the elections.
Read at source →
Top MAHA adviser Calley Means resigns from White House days ahead of midterms
The surprising departure of Calley Means comes just before an election that may serve as a referendum on the MAHA…
Read at source →
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in…
Read at source →
STAT+: Crackdowns loom, from China to New York
Speaking on the economy, the vice president told a crowd in Ohio that, “You don’t turn the Titanic around overnight.”…
Read at source →
STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to…
Read at source →
STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
The Moderna-Merck cancer vaccine data reveal is days away. Here's what to expect.
Read at source →
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
In this edition of STAT Health Tech: FDA's guidance on prescription drug use-related software, and telehealth pushing…
Read at source →
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
Working-age U.S. adults without health insurance rose in 2026. Half of all uninsured people did not seek needed care…
Read at source →
STAT+: Workers are paying 9% more for family health coverage this year, a higher jump than in the recent past
A KFF survey finds that rising healthcare costs are squeezing both employers and workers.
Read at source →
Opinion: What I got wrong about the Affordable Care Act — and how to fix it
“The big mistake, ironically, was the ACA’s lack of focus on affordability,” writes Dana Goldman.
Read at source →
Opinion: The inherited disease my family called ‘it’ had a name, which changed everything
For 50 years, doctors shrugged about the disease running through Miranda Pappas’ family. Then she discovered something.
Read at source →
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
As telehealth promotes GLP-1s for addiction, experts worry about fragmented care, and exposing patients to unknown…
Read at source →
STAT+: CMS extends fraud crackdown to New York’s adult day care program
CMS is cracking down on adult day cares in New York, part of a broader focus on alleged health care fraud.
Read at source →
STAT+: Another diabetes association leader is out while review continues
An endocrinologist who had long served in the American Diabetes Association's leadership is out without explanation.
Read at source →
STAT+: What’s the deal with Isomorphic Labs?
In this edition of STAT's AI Prognosis: What does Isomorphic Labs' high valuation say about AI's role in drug…
Read at source →
STAT+: GSK picks up hep B drug approval
GSK has won FDA approval for its hepatitis B drug, which extended functional cures to far more patients than previous…
Read at source →STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
Mark Cuban has a new vision for his company Cost Plus Drugs: shake up the business of custom-made rare disease medicines
Read at source →
STAT+: Roivant says closely watched immune drug succeeded in new eye disease
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye…
Read at source →
Nigeria identifies travel-related Ebola case
Nigeria has confirmed an imported Ebola case tied to the ongoing outbreak centered in the Democratic Republic of the…
Read at source →
A counterintuitive way to build trust in measles vaccines and public health
Some experts say public health messaging would be more credible if it focused less on measles deaths and acknowledged…
Read at source →
STAT+: Mark Cuban wants to crack open the market for rare disease treatments
Mark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene…
Read at source →
Opinion: Replication is necessary even if scientists do everything right
“Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. Ramos
Read at source →
Opinion: How knocking on doors can help beat measles — again
“As measles outbreaks spread in the U.S., it may be time to learn how other countries get their outbreaks under…
Read at source →
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results…
Read at source →
STAT+: He’s slashing quality at nursing homes. This state is letting it happen
The Boston Globe Spotlight Team found Eli Mirlis made grim cuts to resident care while steering millions of dollars…
Read at source →
STAT+: State regulators move to seize licenses from nursing home chain that was focus of Boston Globe investigation
A Boston Globe investigation found that RegalCare acquired nursing homes across Massachusetts, then gutted the quality…
Read at source →
STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
A bipartisan group of lawmakers is urging the FDA to plug a loophole used to import knockoff retatrutide, an…
Read at source →
STAT+: Roche continues to look to China for new drugs
China's Hansoh Pharmaceutical Group has announced that it struck a massive deal with Roche to develop a portfolio of…
Read at source →
Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary
A reporter who interviewed Elizabeth Holmes on why society confuses authenticity, honesty, and truth, and how she takes…
Read at source →
STAT+: OpenEvidence’s JAMA paper leaves open questions
In this edition of STAT Health Tech: A new paper in JAMA offers a glimpse into clinicians's use of OpenEvidence, and a…
Read at source →STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
The median net price for newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35%…
Read at source →
How voters feel about trans rights and abortion access will soon be put to the test
How do voters feel about trans students participating in school sports teams? Or abortion access? The U.S. is about to…
Read at source →
STAT+: Dana-Farber, Beth Israel to begin construction of new $1.68 billion cancer hospital
Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting work on a $1.68 billion cancer hospital in…
Read at source →